drugset / Trial / NCT05636267
Study of AK119 and AK112 With or Without Chemotherapy for NSCLC Patients
Non-randomizedSequentialOpen-labelTreatment
Summary
This is a phase Ib/II study to evaluate the safety, tolerability, pharmacokinetics, and anti-tumor activity of AK119 and AK112 With or Without Chemotherapy for NSCLC patients.
Timeline
- Start
- 2023-02-10
- Primary completion
- 2025-02-24
- Completion
- 2025-04-15
Outcome
Outcome not reported
Stopped (Business): “Terminated due to sponsor strategic development reprioritization.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | AK119 | Monoclonal antibody | — | Intravenous |
| Subject | Carboplatin | Small molecule | — | Intravenous |
| Subject | Ivonescimab | Monoclonal antibody | — | Intravenous |
| Subject | Pemetrexed | Small molecule | — | Intravenous |